Article Details

Merck gains FDA priority nod for sGC stimulator vericiguat in heart failure

Retrieved on: 2021-01-20 18:45:00

Tags for this article:

Click the tags to see associated articles and topics

Merck gains FDA priority nod for sGC stimulator vericiguat in heart failure. View article details on hiswai:

Excerpt

V2 is able to escape neutralization by both monoclonal antibodies and ... Its two lead candidates are a clinical stage monoclonal antibody targeting ...

Article found on: www.bioworld.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo